Specialty Pharma Underperforms S&P 500 For First Time Since 2009Bala Murali Krishna
As the year winds down, good riddance might be a popular sentiment for specialty pharma, which underperformed against the S&P 500 for the first time since 2009 as Martin Shkreli, Epipen "gauging" and Valeant "scandal" stories took their toll. But the theme for 2017 might not be a whole lot better. Try uncertainty.
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email firstname.lastname@example.org and we will get back to you as quick as humanly possible